Remove 2023 Remove Pharmaceutical manufacturing Remove Prescription Remove Safety
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Actavis, 570 U.S. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

The combined solution enables health plans and self-insured employers to realize immediate pharmacy cost savings and near-term medical cost reductions by integrating Levrx’s plan-specific and real-time prescription insights into the Adhere Platform medication optimization offerings. The Andaman7 Platform Solution. Vincent Keunen.

article thumbnail

Everything You Need to Know About Market Access in China

PM360

market (source: IQVIA MIDAS, May 2023). At the same time, a “drug lag” persists in China for global pharmaceutical companies’ products. billion people in 2023). Medicines that are not listed in either Category 1 or 2, such as over the counter (OTC) and other prescription therapies (pembrolizumab, CAR-T therapy, etc.),

Marketing 105